ATX Register Accolade Stem & Trident/Tritanium Cup With X3 Insert

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

472 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2024-11-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this register is to determine the Accolade/Accolade II stem and Trident/Tritanium cup survivorship over years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Navigation With X3 vs Non-Navigation With X3 Study

NCT02543463

Degenerative Joint Disease

COMPLETED NA

Registry in Patients With Thoracoabdominal Aneurysms

NCT03295682

Thoracoabdominal Aneurysm

ACTIVE_NOT_RECRUITING

Global Post-market Registry for the Treovance Stent-graft.

NCT03449875

Abdominal Aortic Aneurysm

COMPLETED

Vascutek Anaconda™ Abdominal Aortic Aneurysm (AAA) Post-Market Surveillance Registry

NCT01744119

Abdominal Aortic Aneurysm

TERMINATED

Evaluation of Mechanical Stapler for Aortic Anastomoses

NCT00319475

Aortic Aneurysm, Abdominal Leriche Syndrome

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective international multicentre surveillance register. The aim of this register is to determine the Accolade/Accolade II stem and Trident/Tritanium cup survivorship over years. All institutions willing to participate to the register, able to recruit at least 20 patients (up to 100 patients)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthroplasty, Replacement, Hip

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Accolade stem

All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.

Group Type ACTIVE_COMPARATOR

Accolade stem

Intervention Type DEVICE

Total hip replacement

Trident/Tritanium cup

Intervention Type DEVICE

Total hip replacement

Accolade II stem

All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.

Group Type ACTIVE_COMPARATOR

Accolade II stem

Intervention Type DEVICE

Total hip replacement

Trident/Tritanium cup

Intervention Type DEVICE

Total hip replacement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Accolade stem

Total hip replacement

Intervention Type DEVICE

Accolade II stem

Total hip replacement

Intervention Type DEVICE

Trident/Tritanium cup

Total hip replacement

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and non-pregnant female patients between 18-75 years of age.
2. Patients requiring uncemented primary Total Hip Arthroplasty (THA), suitable for the use of the Accolade stem and Trident/Tritanium cup.
3. Patients with a diagnosis of osteoarthritis (OA).
4. Patients who understand the conditions of the study and are willing and able to comply with the post-operative scheduled clinical and radiographic evaluations and the prescribed rehabilitation.
5. Patients who signed the Ethics Committee approved Informed Consent Form prior to surgery.

Exclusion Criteria

1. Patients who require revision of a previously implanted hip prosthesis.
2. Patients who had a THA on contralateral side within the last 6 months.
3. Patients who had a THA on contralateral side more than 6 months ago and the rehabilitation period outcome was considered unsatisfactory or not good (Harris Hip Score \< 85).
4. Patients who will need lower limb joint replacement for another joint within one year.
5. Patients requiring bilateral hip replacement.
6. Patients who have had a prior procedure of acetabular osteotomy.
7. Patients with acute femoral fractures
8. Obese patients where obesity is severe enough to affect subject's ability to perform activities of daily living (body mass index, kg/m2: BMI ≥ 35).
9. Patients with active or suspected infection.
10. Patients with malignancy - active malignancy.
11. Patients with severe osteoporosis, rheumatoid arthritis (RA), Paget's disease or renal osteodystrophy.
12. Patients immunologically suppressed, or receiving steroids in excess of physiologic dose requirements.
13. The patient has a neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device or the patient has a neurological deficit which interferes with the patient's ability to limit weight bearing or places an extreme load on the implant during the healing period.
14. Female patients planning a pregnancy during the course of the study.
15. Patients with systemic or metabolic disorders leading to progressive bone deterioration.
16. Patients, who as judged by the surgeon, are mentally incompetent or are unlikely to be compliant with the prescribed post-operative routine and follow-up evaluation schedule.
17. Patients with other severe concurrent joint involvements, which can affect their outcome.
18. Patients with other concurrent illnesses, which are likely to affect their outcome such as sickle cell anaemia, systemic lupus erythematosus or renal disease requiring dialysis.
19. Patient with a known sensitivity to device materials.
20. Patients under the protection of law (e.g. guardianship).

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No